Show simple item record

dc.contributor.authorBridgewater, Jen_US
dc.contributor.authorLopes, Aen_US
dc.contributor.authorPalmer, Den_US
dc.contributor.authorCunningham, Den_US
dc.contributor.authorAnthoney, Aen_US
dc.contributor.authorMaraveyas, Aen_US
dc.contributor.authorMadhusudan, Sen_US
dc.contributor.authorIveson, Ten_US
dc.contributor.authorValle, Jen_US
dc.contributor.authorWasan, Hen_US
dc.date.accessioned2017-03-24T14:31:51Z
dc.date.issued2016-04en_US
dc.identifier.citationBritish journal of cancer, 2016, 114 (9), pp. 965 - 971en_US
dc.identifier.issn0007-0920en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/504
dc.identifier.eissn1532-1827en_US
dc.identifier.doi10.1038/bjc.2016.64en_US
dc.description.abstract<h4>Background</h4>The ABC-02 (Advanced Biliary Tract Cancer) study established cisplatin and gemcitabine (CisGem) as the standard first-line chemotherapy for patients with locally advanced or metastatic biliary tract cancer (BTC). We examine quality of life (QoL), describe the long-term survivors and provide a long-term outcome.<h4>Methods</h4>A total of 410 BTC patients were randomised to receive either CisGem or gemcitabine alone (Gem); 324 patients consented to complete EORTC QLQ-C30 and EORTC QLQ-PAN26 QoL questionnaires; 268 (83%) patients returned at least one QoL questionnaire (134 in each arm). Long-term survivors were defined as those surviving over 2 years and we performed a final analysis of the primary outcome; overall survival (OS).<h4>Results</h4>Most QoL scales showed a trend favouring the combined CisGem arm, including functional and symptomatic scales, although the differences were not statistically significant. Forty-five (11%)) patients survived at least 2 years (34 received CisGem and 11 Gem) and 21 (5%) 3 years or more (14 received CisGem and 7 Gem). After a median follow-up of 9.2 months and 398 deaths, the median OS was 11.7 months for CisGem and 8.1 months for Gem (hazard ratio (HR)=0.65, 95% CI: 0.53-0.79, P<0.001).<h4>Conclusions</h4>The survival advantage of CisGem compared to Gem was not associated with an improvement or deterioration of QoL. Long-term survivors were more likely to have received CisGem and the long-term OS is identical to that previously described.en_US
dc.formatPrinten_US
dc.format.extent965 - 971en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserveden_US
dc.subjectHumansen_US
dc.subjectBiliary Tract Neoplasmsen_US
dc.subjectTreatment Outcomeen_US
dc.subjectQuality of Lifeen_US
dc.subjectSurvivorsen_US
dc.subjectFemaleen_US
dc.subjectMaleen_US
dc.titleQuality of life, long-term survivors and long-term outcome from the ABC-02 study.en_US
dc.typeJournal Article
dcterms.dateAccepted2016-02-16en_US
rioxxterms.versionofrecord10.1038/bjc.2016.64en_US
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc-sa/4.0en_US
rioxxterms.licenseref.startdate2016-04en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfBritish journal of canceren_US
pubs.issue9en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume114en_US
pubs.embargo.termsNot knownen_US
icr.researchteamMedicine (RMH Smith Cunningham)en_US
dc.contributor.icrauthorCunningham, Daviden_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record